Ovation Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Focusing on unmet needs in CNS and oncology, Ovation Pharmaceuticals Inc. will acquire marketed drugs and late-stage candidates that don't represent a big enough payoff to their current manufacturers. The company plans to boost its acquisitions' value by developing new dosages, new formulations and new treatment indications, then add creative sales and marketing muscle to bring its products to the light of day.
You may also be interested in...
The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities
Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.
The Billion Dollar REMS: Xenazine and the Value of Facing Regulatory Realities
Prestwick's Huntington's chorea therapy won FDA approval in August, triggering a flurry of deals valued at over $1 billion. Not bad for a 50-year-old drug expected to treat no more than 5,000 patients-and a powerful case study in how embracing the new regulatory realities can pay off.
Chester Valley Pharmaceuticals Inc.
In a year that saw a number of significant private financings in dermatology, Chester Valley Pharmaceuticals Inc. was one of the standouts. The specialty pharma was formed in November 2004 by dermatology industry veterans Robert J. Moccia and Xavier Yon, and by private equity firm GTCR Golder Rauner LLC, which has made a $75 million equity commitment to the new company.